Navigation Links
How to select anti-hepatitis B virus agents for drug-resistance patients?
Date:9/24/2008

HBV infection may lead to acute liver disease, chronic active hepatitis, liver cirrhosis, and hepatocellular carcinoma. Over 350 million people worldwide are estimated to be infected chronically by HBV and are therefore at risk of liver failure, cirrhosis, or hepatocellular carcinoma. The principal treatment for chronic hepatitis B (CHB) involves the use of interferon alpha (IFN-a) or nucleoside analogs. In vitro analysis of clinical HBV isolates is currently difficult for lacking of HBV cellular culture model

A research article to be published on 14 June 2008, in the World Journal of Gastroenterology addresses this question. The research team led by Prof. Yin-Ping Lu from Union Hospital of Tongji Medical College reportd a useful strategy to select anti-HBV agents for drug-resistance patients. The full-length HBV genomic DNA from chronic hepatitis B patients were amplified by polymerase chain reaction (PCR). The amplified HBV DNA fragments were inserted into an universal HBV expression vector respectively. The recombinant plasmids containing 1.1 copies of HBV genome were transient transfected into Huh7 cells and antiviral susceptibility of lamivudine and adefovir were analyzed in vitro model system. Furthermore, the antiviral susceptibility of adefovir in vivo were observed subsequently.

Eight clinical HBV isolates form different individual with lamivudine-resistance were cloned into HBV expression vector, and recombinant plasmids were transcient transfected into Huh7 cells. The results indicated that HBV genome of clinical HBV isolates could effectively replicate and be expressed in Huh7 cells. Adefovir but not lamivudine inhibited HBV replication both in vitro and in vivo.

The novel method described in this article enables rapidly selecting of anti-HBV agents in clinic and will be useful in future studies of antiviral therapy for chronic hepatitis B.


'/>"/>

Contact: Lai-Fu Li
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Page: 1

Related medicine news :

1. Brooke Franchise Corporation Announces Selected July Results
2. Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
3. Corbett Selected to Host the Only Midwest Global Awards Judging Competition
4. Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing relationship
5. Crdentia Selected by High Rock Raceway to Provide Healthcare Staffing Services
6. Mindray Selects Actel Low-Power Flash FPGAs for Demanding Medical Equipment Applications
7. Purdue Pharma Selects Systech to Provide Sustainable Infrastructure for Serialization
8. Harvard Researchers Select S.C. BlueCross for National Honor
9. Loma Linda University Medical Center Selects Beryl to Manage Call Center Interactions for Womens Services Programs and Departments
10. Fry Construction Selected for High-Profile Medical Imaging Project
11. Meth Project Advertisements Selected for National Prevention Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 24, 2016 , ... Southern Illinois University School of Dental ... Illinois State Dental Society (ISDS) Foundation’s Mission of Mercy (MOM). They will host ... Collinsville. , They expect to treat approximately 2,000 patients from Illinois, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... a not-for-profit organization responsible for clinical transfusion research programs and for the blood ... Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) study. , Currently ...
(Date:6/23/2016)... ... June 23, 2016 , ... SyncDog, Inc. , ... security software, is featured in the current issue of Silicon Review ... with innovative technology solutions and features them in their magazine. The magazine allows ...
(Date:6/23/2016)... ... 23, 2016 , ... Horizon Blue Cross Blue Shield of ... from the crushing burden of sky-high health care costs, Superior Court of New ... ( http://www.judiciary.state.nj.us/opinions/a2913-15a2929-15.pdf ) the court provided some analysis of the contracts between ...
(Date:6/23/2016)... ... ... A key metric of this success is the popularity of the Leafedin.org service ... areas that lack the kind of technology and networking framework that LeafedIn.org provide, where ... the marijuana industry, no matter how small or large, and more importantly no matter ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
Breaking Medicine Technology: